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Introduction
Tumors have a complex cellular ecology that establishes the 
malignant potential of the tumor. In these ecosystems, innate 
immune cells are highly represented, and among the most 
abundant of these are macrophages. Although the original 
hypotheses proposed that macrophages are involved in anti-
tumor immunity, there is substantial clinical and experimental 
evidence that in the majority of cases these tumor-associated 
macrophages (TAMs) enhance tumor progression to malig-
nancy. The tumor-promoting functions of macrophages at the 
primary site include supporting tumor-associated angiogen-
esis, promotion of tumor cell invasion, migration, and intrava-
sation, as well as suppression of antitumor immune responses 
(Condeelis and Pollard, 2006; Pollard, 2004). Macrophages 
also potentiate the seeding and establishment of metastatic 
cells and play a role in tumor initiation when inflammation is 
a causal factor. This review focuses on the diverse roles and 
functions of macrophages in the primary tumor and at meta-
static sites. Accumulating evidence suggests that tumor ini-
tiation, progression, and metastasis are affected by dynamic 
changes in the phenotypes of macrophages and that defined 
subpopulations of macrophages are responsible for these 
tumor-promoting activities.
Macrophage Phenotypes
Macrophages are differentiated cells of the mononuclear 
phagocytic lineage (Pollard, 2009, and references therein) that 
are characterized by specific phenotypic characteristics and 
by the expression of particular markers, none of which are 
entirely restricted to the lineage (Gordon and Taylor, 2005). In 
mice, macrophages are phagocytic and express CD11b, F4/80, 
and colony-stimulating factor-1 receptor (CSF-1R; CD115) and 
do not express Gr1 (more specifically, Ly6G that is detected by 
anti-Gr1 antibodies). In humans, phagocytosis, CD68, CD163, 
CD16, CD312, and CD115 are the major markers of the lineage. 
When combined, these characteristics discriminate mac-
rophages from other members of the myeloid lineage such as 
the polymorphonuclear neutrophils and eosinophils (Joyce and 
Pollard, 2009).
Macrophage origins, lineage, and regulation by growth fac-
tors have been recently reviewed, and attempts have been 
made to define macrophage subsets (Pollard, 2009, and refer-
ences therein). The most successful classifications have been 
applied to subtypes participating in particular immunological 
responses. These include the “activated” macrophage involved 
in the responses of type I helper T (Th1) cells to pathogens. 
This population is activated by interferon gamma and engage-
ment of Toll-like receptors (TLRs) and is characterized by ele-
vated expression of major histocompatibility complex (MHC) 
class II, expression of interleukin (IL-12) and tumor necrosis 
factor α (TNFα), generation of reactive oxygen species and 
nitric oxide (NO), and the ability to kill pathogens and cells. 
In contrast, the “alternatively activated” macrophages that dif-
ferentiate in response to IL-4 and IL-13 are involved in Th2-type 
responses, including humoral immunity and wound healing 
(Gordon, 2003). Another population is the antigen-presenting, 
migratory dendritic cells that are a branch of the mononuclear 
phagocytic lineage. There are also other macrophage popu-
lations involved in tissue development and homeostasis that 
are largely regulated by CSF-1 and that do not fall easily into 
these immunological categories (Pollard, 2009). This argues 
that there are many populations of macrophages ranging from 
trophic macrophages involved in developmental processes 
(often with specialized functions such as the bone-remodeling 
osteoclast) to those active in tissue repair and the immunologi-
cal subsets described above (Pollard, 2009). Mantovani and 
collaborators have suggested that macrophages in tumors are 
biased away from the activated (M1) to the alternatively acti-
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vated type named “M2” (Mantovani and Sica, 2010). Recent 
gene profiling experiments on TAMs support this shift to an 
immunoregulatory type (Biswas et al., 2006; Ojalvo et al., 2009; 
Pucci et al., 2009). However, in contrast to this binary M1/M2 
definition, TAMs are composed of several distinct populations 
that often share features of both types, but with greater over-
all similarity to macrophages involved in developmental pro-
cesses (Ojalvo et al., 2009; Ojalvo et al., 2010). The functions of 
these subpopulations in promoting malignancy are discussed 
below.
Macrophages and Cancer
Clinical studies make a strong case that macrophages promote 
tumorigenesis. In one metaanalysis, it has been reported that 
over 80% of studies show a correlation between macrophage 
density and poor patient prognosis (Bingle et al., 2002), and 
recent studies have further supported this conclusion. For 
example, there is a strong association between poor survival 
and increased macrophage density in thyroid, lung, and hepa-
tocellular cancers (Chen et al., 2005; Ryder et al., 2008; Zhu et 
al., 2008). However, as before there are some exceptions with 
high macrophage densities correlating with increased survival 
in pancreatic cancer (Kim et al., 2008). An unbiased transcrip-
tome analysis of follicular lymphoma shows that a macrophage 
transcriptional signature is a predictor of a poor prognosis, 
as is increased macrophage density (Farinha et al., 2005). 
Analysis of the transcriptome of TAMs derived from studies in 
mouse models of breast cancer has also provided evidence 
that an enrichment in macrophage transcripts is predictive of 
poor prognosis and reduced survival in human breast cancer 
(Ojalvo et al., 2009; Zabuawala et al., 2010).
Macrophage differentiation, growth, and chemotaxis are 
regulated by several growth factors, including CSF-1, gran-
ulocyte-macrophage (GM)-CSF, IL-3, and chemokines such 
as CCL-2 (Pollard, 2009). Overexpression of CSF-1, the major 
lineage regulator for macrophages (Pollard, 2009), is asso-
ciated with poor prognosis in breast, ovarian, endometrial, 
prostate, hepatocellular, and colorectal cancer, among others 
(Groblewska et al., 2007; Lin et al., 2002; Mantovani and Sica, 
2010; Mroczko et al., 2007; Sapi and Kacinski, 1999; Smith 
et al., 1995; Zhu et al., 2008). CCL-2 is also overexpressed 
in a wide range of cancers (Mantovani and Sica, 2010) and 
is associated with poor prognosis in breast, colorectal, and 
thyroid cancers (Bailey et al., 2007; Saji et al., 2001; Tanaka 
et al., 2009; Yoshidome et al., 2009), whereas its absence is 
associated with increased survival in cervical cancer patients 
(Zijlmans et al., 2006). In melanoma, there appears to be an 
inverse relationship between CSF-1 and CCL2 expression, 
although in this case TAM density still correlates with inva-
siveness and poor prognosis (Varney et al., 2005). A CSF-1 
response transcriptional signature has been found in ductal 
carcinoma in situ (DCIS) of the breast (Sharma et al., 2009) 
and in a subset of breast cancers where it correlates with 
higher tumor grade (Beck et al., 2009). In leiomyosarcomas, 
the CSF-1 expression signature has been reported as the only 
independent prognosticator in multivariate analysis (Espinosa 
et al., 2009). These association studies are highly suggestive 
of the involvement of these growth factors and chemokines 
in tumor macrophage biology. However, a note of caution 
should be added for this interpretation, given that in some 
cases tumor cells express the receptors for these growth 
factors and chemokines and this expression can result in an 
increased malignant phenotype (Mantovani et al., 2008; Pat-
sialou et al., 2009; Scholl et al., 1994; Smith et al., 1995).
Experimental evidence for the tumor-promoting activation of 
macrophages has been derived from several different types of 
experiments. Genetic ablation of the macrophage growth fac-
tor CSF-1 in the polyoma middle T (PyMT) oncoprotein mouse 
model of breast cancer greatly reduces macrophage density in 
tumors, slows the rate of tumor progression to malignancy, and 
severely inhibits metastasis (Lin et al., 2001). In these studies, 
macrophages are the only cells expressing the CSF-1 receptor 
(CSF-1R). Overexpression of CSF-1 in wild-type tumors results 
in earlier macrophage recruitment and an accelerated rate of 
tumor progression and increased metastasis. Genetic ablation 
of CSF-1 also affects tumor development and reduces malig-
nancy in a genetic model of colon cancer (Oguma et al., 2008) 
and in an osteosarcoma xenotransplant model (Kubota et al., 
2009). Furthermore, genetic ablation in myeloid cells of the Est-2 
transcription factor, a direct effector of the CSF-1 pathway, 
results in an inhibition of metastasis in both PyMT and orthoto-
pic transplant breast cancer models (Zabuawala et al., 2010).
Similar results have been obtained with therapeutic 
approaches. Treatment with antisense or antibodies that inhibit 
CSF-1 or its receptor reduces macrophage recruitment or 
function in mice bearing xenotransplants of human tumor cells, 
thereby inhibiting tumor growth and metastasis (Abraham et 
al., 2010; Aharinejad et al., 2009). Further, specific depletion 
of macrophages using clodronate-encapsulated liposomes 
reduces growth in melanoma, ovarian, Lewis lung, teratocar-
cinoma, rhabdomyosarcoma, and prostate tumor graft models 
(Gazzaniga et al., 2007; Halin et al., 2009; Kimura et al., 2007; 
Robinson-Smith et al., 2007; Zeisberger et al., 2006).
It should be recognized, however, that although the experi-
mental and clinical data largely support the hypothesis that 
macrophages promote malignancy, there are exceptions. For 
example, in the bone marrow, macrophages play a gatekeeper 
role by phagocytosing cells that do not express the antide-
ath receptor CD47. Leukemic cells upregulate this receptor to 
escape destruction (Jaiswal et al., 2009). Older data also show 
that liver macrophages (known as Kupffer cells) engulf and kill 
circulating tumor cells, such that the depletion of Kupffer cells 
in rats enhances metastasis (Heuff et al., 1993). Further, in peri-
toneal xenograft experiments in which cancer cells “metasta-
size” to the liver, depletion of Kupffer cells worsens the prog-
nosis. In addition, these tumors exhibit greater differentiation 
and less malignancy but grow faster in the absence of mac-
rophages, the mice dying of an increased tumor load (Oost-
erling et al., 2005). Thus, although these experiments provide 
further support for a role for macrophages in malignant pro-
gression, ironically, the outcome of their depletion was earlier 
death. These data contrast with the observations that Kupffer 
cells provide essential mitogens to hepatocellular carcinoma. 
The mitogen synthesis is due to NFκB signaling in these cells, 
and ablation of their NFκB signaling results in a reduction in 
tumor burden (Karin and Greten, 2005).
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Although the dynamics within tumors is undoubtedly com-
plex, with macrophages playing both positive and negative 
roles, the data from animal models as well as from the clini-
cal correlates indicate that in the vast majority of cases mac-
rophages promote tumor progression and metastasis.
Macrophages in Cancer Initiation and Promotion
There is a growing appreciation that inflammation is the root 
cause of many cancers. Mantovani and colleagues have called 
this the seventh hallmark of cancer and reviewed its characteris-
tics as well as the epidemiological and infectious disease litera-
ture that supports this hypothesis (Mantovani and Sica, 2010). A 
causal basis for the role of inflammation in cancer initiation has 
direct experimental support. In humans, chronic obstructive pul-
monary disease is associated with persistent colonization with 
the bacterium Haemophilus influenzae and leads to increased 
lung cancer risk. In a mouse model of lung cancer, bronchial 
exposure with H.influenzae lysate results in inflammation in 
the lung and an increase in tumorigenesis (Moghaddam et al., 
2009). Myeloid-specific ablation of intergrin αV also results in an 
ulcerative colitis that induces colonic tumors (Lacy-Hulbert et 
al., 2007). Ablation in myeloid cells of Stat3, a transcription factor 
whose function suppresses inflammatory responses because it 
Figure 1. Macrophages Promote Tumor Initiation, Progression, and 
Malignancy
(A) Chronic smoldering inflammation in response to pathogens or irritants 
creates a mutagenic and growth-promoting environment in the subepithelial 
stroma. This environment potentiates the acquisition of oncogenic mutations 
in the overlying epithelial cells. Central to the inflammatory process are acti-
vated macrophages, which are the major producers of reactive oxygen and 
nitrogen species as well as a wide range of growth factors.
(B) Spontaneous or hereditary mutations cause tumor initiation and progres-
sion in cancers not associated with inflammation.
(C) The hyperplastic lesions progress to an intraepithelial neoplasia. This 
process results in the recruitment of monocytes by chemoattractants from 
the blood, such as colony stimulating factor-1 (CSF-1) and the chemokine 
CCL-2. These monocytes differentiate into macrophages in the tumor. These 
macrophages, unlike those in the initiating inflammatory environment, are not 
classically activated but instead resemble trophic, immunomodulatory mac-
rophages found during development.
(D) The transition from an intraepithelial neoplasia/adenoma to an early car-
cinoma is promoted by macrophages in part through their stimulation of the 
angiogenic switch. Macrophages deliver vascular endothelial growth factor 
(VEGF) and other angiogenic molecules in a temporal and spatial fashion to 
avascular areas, resulting in angiogenesis. In addition, macrophages produce 
growth factors and proteases that facilitate the escape of tumor cells from 
their constraining basement membranes. Furthermore, macrophages sup-
press cytotoxic T cell responses to the invading tumor cells.
(E) After progression to malignancy, and as tumors because late carcinomas, 
macrophages are continuously recruited through similar mechanisms as be-
fore. In the tumor they differentiate into different subpopulations that have 
functions in: (1) angiogenesis, (2) tumor cell invasion and intravasation, and 
(3) immunosuppression. 
(F) The box in (E) designates an invasive microenvironment as defined in 
mouse models of breast cancer. In this model, tumor cell motility and invasion 
(dotted line) are sparked by the production of growth factors/chemokines, 
such as CXCL12 that binds to its receptor (CXCR4) expressed on both mac-
rophages and tumor cells. Once motility is initiated, it is driven by an obli-
gate epidermal growth factor (EGF)-CSF-1 paracrine loop with macrophages 
and tumor cells moving in lock step. Invasion also requires matrix formation 
and destruction through cathepsins and SPARC. Macrophages promote vas-
culogeneisis through angiogenic factors such as VEGF. Tumor cells egress 
through macrophage clusters on the blood vessels, and thus the macrophag-
es increase both the invasion/intravasation of tumor cells and the number of 
vascular targets. This allows increased numbers of tumor cells to enter the 
circulation and thereby enhancement of tumor metastasis.
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is a major target of immunosuppressive cytokine IL-10 (Yu et al., 
2007), causes inflammation in the colon. This is associated with 
abundant expression of TNFα and IL-6 by macrophages and 
results in a chronic colitis and invasive colonic adenocarcino-
mas (Deng et al., 2010). Similarly, global ablation of IL-10 also 
results in chronic colitis and intestinal tumors (Yu et al., 2007). 
Mice that have a genetic ablation of GM-CSF (Csf2) and inter-
feron γ (Ifg), whose loss would compromise acquired immune 
responses to pathogens, are found to develop a wide range of 
cancers (Enzler et al., 2003). The causality of the inflammation 
in carcinogenesis in these studies comes from experiments in 
which suppression of the bacterial flora by antibiotic treatment 
reduces the inflammation and inhibits tumorigenesis (Berg et al., 
1996; Deng et al., 2010; Enzler et al., 2003). These data argue 
that the immune system is normally in balance but that once 
the negative controls of immune responses are compromised, 
a persistent inflammatory response to normally commensal 
organisms results. This inflammation in turn creates a tumor-
promoting microenvironment.
The inflammatory state in myeloid cells is controlled by the 
transcriptional factors NFκB and STAT3 that work in opposi-
tion to one another (Karin and Greten, 2005; Yu et al., 2007). 
NFκB is a central transducer of signals that cause inflammation 
downstream of TLR activation. Its activity results in expression 
of inflammatory cytokines such as IL-12 and TNFα, as well as 
inducible nitric oxide synthase (iNOS) (Karin and Greten, 2005). 
In the inflammatory responses associated with cancer initia-
tion, NFκB signaling is essential for the inflammatory pheno-
type (Karin and Greten, 2005). Inhibition of this activity through 
ablation of IκB kinase α (IKKα) in myeloid cells in mouse mod-
els of intestinal cancer reduces inflammation and inhibits tumor 
progression (Greten et al., 2004).
The type of inflammation associated with increased can-
cer risk because of chronic infection or persistent irritation is 
often called “smoldering inflammation” (Mantovani and Sica, 
2010). This nomenclature is used because the inflammation is 
low grade without overt clinical consequences. Activated mac-
rophages are central to this type of immune response and work 
in concert with other immune cells (Balkwill et al., 2005). It has 
been hypothesized that these immune cells produce a muta-
genic environment (Pang et al., 2007) by generating both reac-
tive nitrogen and oxygen species. NO in particular reacts with 
peroxidates to give nitrosoperoxycarbonate, and this reaction 
is a major driver of the chemistry of inflammation. This highly 
reactive compound and other products cause mutations in the 
adjacent epithelial cells (Meira et al., 2008; Pang et al., 2007). 
In addition, there is evidence that the inflammatory microenvi-
ronment also promotes genetic instability within the develop-
ing tumor epithelial cells (Colotta et al., 2009). In either case, 
the mutations are fixed after replication of the epithelial cells, a 
process that is stimulated by growth factors synthesized by the 
infiltrating or resident immune cells that include macrophages. 
These growth-promoting effects on tumors are caused by the 
production of IL-6 in hepatocellular carcinoma (HCC) (Lin and 
Karin, 2007; Naugler et al., 2007) and TNFα (Karin et al., 2006) 
and IL-6 in colitis associated cancers (Grivennikov et al., 2009). 
Interestingly, IL-6 synthesis in Kupffer cells in response to 
inflammation-induced liver damage is gender dependent with 
males who have increased risk of HCC having elevated levels. 
IL-6 is also required for the increased risk of HCC in female 
mouse models (Naugler et al., 2007).
Classical models of skin carcinogenesis show that onco-
genic mutations caused by low but not initiating doses of car-
cinogens (such as dimethybenzanthracene) need to be “fixed” 
by application of a tumor promoter. The promoter application 
causes an acute inflammatory response that is dominated by 
macrophages. TNFα action through NFκB is a causal agent in 
this promotion through mechanisms that act directly on epi-
thelial cells and on the inflammatory cells in the surrounding 
stroma, particularly the macrophages (Balkwill, 2009). Simi-
lar mechanisms operate in colon cancer (Luo et al., 2004). 
Together, these data strongly support causal roles for inflam-
mation in cancer initiation and promotion. Although not defini-
tive, given that macrophages have not been uniquely targeted 
in any system, the data suggest that macrophages are key 
cells in cancer induced by inflammation.
Macrophage Functions in the Primary Tumor
The macrophage phenotype associated with cancer ini-
tiation and promotion is comparable to the “activated” one 
(Gordon, 2003). However, once initiated and as the tumors 
progress toward malignancy, the macrophage phenotype 
changes from the “inflammatory” type to one that resembles 
macrophages that promote tissue formation during develop-
ment (Figure 1) (Pollard, 2004, 2009). In established tumors, 
NFκB signaling is inhibited by the constitutive expression of 
p50 homodimers that negatively regulate NFκB and the mac-
rophages display the M2/trophic phenotype with reduced 
iNOS and TNFα expression (Saccani et al., 2006). Indeed, 
blocking NFκB function by inhibition of IKKα in cultured 
macrophages reduces the inflammatory gene expression 
signature and pushes cells to the trophic/M2 type (Porta et 
al., 2009). This transition from stimulated to inhibited NFκB 
function between the initiation and the established tumor 
stages are poorly understood but appears central to mac-
rophage function in the tumor microenvironment. This alter-
natively activated/trophic type of macrophage is also found 
in cancers that arise in the apparent absence of obvious 
inflammation, such as breast cancer, in which macrophages 
are recruited to benign tumors in large numbers just as the 
tumors transition to malignancy (Figure 1).
Macrophage recruitment to tumors has been well-doc-
umented in the PyMT mouse model of breast cancer (Lin et 
al., 2003; Pollard, 2009), where sizeable populations of mac-
rophages are recruited at the adenoma/mammary intraepithe-
lial stage once the tumors have progressed to early malignancy 
(Lin et al., 2003; Lin et al., 2006; Lin et al., 2001; Wyckoff et al., 
2007). Similar patterns also occur in human endometrial and 
breast cancers (Lewis and Pollard, 2006; Smith et al., 1995). 
These macrophages are recruited in the presence of CSF-1, 
which promotes a trophic phenotype, and IL-4 and IL-10, which 
makes them immunomodulatory (DeNardo et al., 2009; Ham-
ilton, 2008; Lin et al., 2001). Thus, it is a misnomer to consider 
the leukocytic infiltrate in established tumors to be “inflamma-
tory,” as there are few of the hallmarks of inflammation, such as 
edema, swelling, and fever.
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Macrophages have the most complex transcriptome known 
(Suzuki et al., 2009). Because of their potential diversity of gene 
products, blood origin, and motile nature, they are ideally suited 
to perform specific tasks in a timely and spatially appropriate 
manner. Thus, despite the fact that macrophages have many 
features in common, distinct tasks appear to require subtypes 
of macrophages. This is the case in the tumor microenviron-
ment where macrophages are put into service to support the 
tumor. These protumoral functions of macrophage subpopula-
tions are discussed below and are indicated in Figure 2.
Tumor Cell Invasion, Migration, and Intravasation
With a combination of intravital imaging and an in vivo assay 
for invasive tumor cells in the PyMT mouse model and in breast 
cancer cell xenografts, macrophages have been shown to be 
required for tumor cell migration and invasion (Condeelis and 
Pollard, 2006). They are the key that unlocks the gate to allow 
tumor cells to escape. Mechanistically, tumor cells synthesize 
CSF-1, which stimulates macrophages to move and produce 
epidermal growth factor (EGF), which in turn activates migra-
tion in the tumor cells (Wyckoff et al., 2004) (Figure 1). The 
macrophages and tumor cells move in lock-step, and inhibition 
of either the EGF or CSF-1 signaling pathways results in inhi-
bition of migration and chemotaxis of both cell types. This is 
despite the fact that the CSF-1 receptor and the EGF receptor 
(ErbB1) are restricted to macrophages and tumor cells, respec-
tively (Wyckoff et al., 2004; Wyckoff et al., 2007). A number 
of experimental systems provide evidence that macrophages 
and tumor cells are sufficient for this EGF-CSF-1 paracrine 
interaction: macrophage-induced migration can be recapitu-
lated with these two cell types in an in vitro collagen overlay 
assay (Condeelis and Pollard, 2006), in mammary epithelial 
organoid culture system (DeNardo et al., 2009), or in coculture 
(Green et al., 2009). However, in this latter case, EGF is not 
involved, whereas CSF-1 is essential. In human breast cancer, 
EGF expression is restricted to macrophages, whereas CSF-1 
is in the tumor cells (Leek et al., 2000; Scholl et al., 1994). In 
PyMT tumor cells, CSF-1 is regulated 
by steroid hormone receptor coactiva-
tor-1 (SRC-1), and in SRC-1’s absence, 
although tumor growth is not affected, 
macrophage recruitment is impaired 
and tumor cell intravasation and metas-
tasis are inhibited (Wang et al., 2009). Macrophage polarization 
to the invasion-promoting phenotype is in turn regulated by IL-4 
synthesized by CD4+ T cells or tumor cells. In the absence of 
IL-4, macrophages are unable to promote invasion, and migra-
tion of tumor cells and metastasis is dramatically reduced in 
the PyMT model (DeNardo et al., 2009; Gocheva et al., 2010).
The comigration of macrophages and tumor cells can be ini-
tiated by other growth factors such as heregulin and CXCL12 
(stromal derived factor-1; SDF-1) dependent on the breast can-
cer model. However, once initiated, the migration of both cell 
types still requires paracrine CSF-1-EGF signaling (Hernandez 
et al., 2009). Given that heregulin and CXCL12 can be syn-
thesized by tumor cells, fibroblasts, or pericytes, these data 
suggest that a specialized microenvironment is formed that 
can initiate tumor cell-macrophage invasion (Figure 1). This 
is consistent with intravital imaging of mammary tumors that 
shows tumor cell invasion is not uniform but occurs sporadi-
cally in particular locations and with observations that tumor 
cell movement in vivo occurs adjacent to macrophages in 
the PyMT mammary tumor model (Wyckoff et al., 2007) and 
in xenotransplants on the chick allantoic membrane (Green et 
al., 2009). Pertinently, CSF-1 expression in human tumors is 
highest at the invasive edge, a site abundantly populated by 
macrophages (Lin et al., 2001; Scholl et al., 1994; Smith et al., 
1995; Zhu et al., 2008).
Other molecules that may be involved in the macrophage 
stimulation of invasiveness in vivo have also been suggested by 
tissue culture experiments. For example, Wnt5a acting through 
the noncanonical pathway (Pukrop et al., 2006) in organoids 
and TNFα via NFκB in coculture (Hagemann et al., 2005) can 
promote tumor cell invasion. Further, macrophages have been 
shown to compensate for the loss of motility in tumor cells after 
a knockdown of osteopontin (SPP1) (Cheng et al., 2007).
The extracellular matrix plays a major role in modifying tumor 
cell invasiveness. Macrophage synthesize SPARC/osteonectin 
(secreted protein, acidic rich in cysteine), which is important 
Figure 2. Macrophage Phenotypes and 
Tumorigenesis
Shown are six macrophage functions that provide 
extrinsic support to a tumor. Each of these extrin-
sic activities can be ascribed to a unique mac-
rophage subpopulation. All of these macrophage 
subtypes are defined by the expression of the 
canonical markers CD11b, F4/80, and CSF-1R, 
as well as absence of Gr1 (Ly6G), but they are 
educated by microenvironmental cues to adopt 
a particular phenotype and perform the tasks as 
shown. The population listed as “perivascular” is 
probably the same as the invasive macrophage 
population as they have similar activities but they 
are localized to the abluminal surface of vessels 
often in cluster. * designates populations whose 
transcriptomes have been analyzed.
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for deposition of collagen IV, enhanced tumor cell invasion, 
and adhesion to other ECM components (such as fibronectin). 
SPARC/osteonectin has been shown to be required for spon-
taneous metastasis from the primary tumor (Sangaletti et al., 
2008). Fibrillar Collagen 1 also enhances the invasion process, 
as tumor cells and macrophages move approximately ten times 
faster on these structures than through the stroma itself. This 
has the unfortunate consequence of recruiting cells toward 
blood vessels given that these collagenous fibrils also anchor 
these structures (Condeelis and Segall, 2003). At least dur-
ing development of the mammary gland, macrophages have 
been shown to promote collagen fibrillogenesis (Ingman et al., 
2006). Intravital imaging has shown that intravasation occurs 
through clusters of macrophages located on the abluminal side 
of the vessels (Wyckoff et al., 2007). Thus, macrophages on 
vessels give come-hither signals that result in tumor cell migra-
tion down collagen fibrils toward vessels where the tumor cells 
escape into the vasculature aided by macrophages. This local-
ized movement near to vessels has been confirmed by intra-
vital imaging of xenografted tumors (Gligorijevic et al., 2009). 
Reduction in the number of tumor-associated macrophages 
using genetic means (Wyckoff et al., 2007) or inhibition of EGF 
(DeNardo et al., 2009; Wyckoff et al., 2007) or CSF-1 (Wyck-
off et al., 2007) signaling in wild-type mice bearing mammary 
tumors reduces the numbers of circulating tumor cells. These 
data suggest that the paracrine loop between the two cell 
types is required for egress into the circulation in vivo (Wyck-
off et al., 2007). Importantly, analysis of clinical material indi-
cates that a structure named the tumor microenvironment of 
metastasis (TMEM), defined by colocalization of macrophages, 
tumor cells, and endothelial cells, is a prognostic marker for 
poor survival in breast cancer (Robinson et al., 2009). These 
data may also tie together the clinical observations described 
above, as CSF-1, EGF, CXCR4 are prognostic markers in many 
cancers.
The macrophages that stimulate tumor cell invasion in 
vivo have been isolated and their transcriptome interro-
gated on DNA microarrays. Unsupervised clustering shows 
this population uniquely separated from a general TAM or a 
reference population of splenic macrophages. Comparisons 
with other data sets show that the “invasive macrophages” 
are most similar to those found during embryogenesis. They 
are enriched in developmental pathways, in particular the 
Wnt signaling pathway (Ojalvo et al., 2010). Given that mac-
rophage-produced Wnts promote vascular remodeling in 
developmental contexts (Lobov et al., 2005), these array data 
led to the hypothesis that these invasive macrophages link 
angiogenesis and tumor invasion.
The studies cited above have focused upon invasion and 
intravasation of single tumor cells typically found in breast can-
cers. However, there are other types of invasion, including the 
collective invasion of sheets of cells such as that found in colon 
cancer. In a mouse model of this disease caused by a mutation 
in the APC gene and hemizygosity of Smad4, a unique popu-
lation of immature myeloid cells (which express CD34, CD45, 
CD11b, and CCR1, but not F4/80) surrounds the invasive front. 
Depletion of CCL9, the ligand for CCR1, blocks the accumula-
tion of these cells with a consequent inhibition of tumor cell 
invasion (Kitamura et al., 2007). These myeloid cells display an 
unusual phenotype, and, as yet, no complete lineage relation-
ship has been established.
Tumor cell migration also requires proteolytic destruction of 
the matrix to allow the escape of tumor cells from the con-
fines of the basement membrane. Subsequently, proteolysis is 
required for tumor cells to migrate through the dense stroma. 
Macrophages are potent producers of many proteases, includ-
ing cathepsins, matrix metalloproteinases (MMPs), and serine 
proteases (Egeblad and Werb, 2002; see Review by K. Kessen-
brock et al. on page 52 of this issue). In many tumors, proteases 
play a role in tumor progression and metastasis (Egeblad and 
Werb, 2002; Gocheva et al., 2006; Joyce and Pollard, 2009). 
Depletion of cathesin B (Gocheva et al., 2010; Vasiljeva et al., 
2006) and S (Gocheva et al., 2010) from macrophages results 
in reduced tumor cell invasion and inhibition of metastasis in 
the PyMT model. Urokinase/Plasminogen activator (uPA) is 
mostly produced by macrophages, and in the PyMT model its 
loss also inhibits metastasis (Almholt et al., 2005). In the colon 
model of collective cell migration described above, the imma-
ture myeloid cells produce both MMP9 and MMP2 that are 
required for the tumor cell invasion (Kitamura et al., 2007).
Angiogenesis
In most tumors, there is a dramatic enhancement of vascu-
lar density from the benign-to-malignant transition, a process 
referred to as the angiogenic switch (Hanahan et al., 1996). The 
formation of a complete vasculature is a complex process with 
many cell types, often with overlapping functions influencing 
its outcome in tumors. Cells of the mononuclear phagocytic 
lineage cells, and macrophages in particular, are major con-
tributors to this process (Zumsteg and Christofori, 2009). Stud-
ies in which macrophages are reduced in mammary tumors 
using the null mutation in the Csf1 gene show that these cells 
are required for the angiogenic switch. This effect is reversed 
by the re-expression of CSF-1 in the mammary epithelium (Lin 
et al., 2006). Overexpression of CSF-1 in wild-type mice results 
in the premature accumulation of macrophages into hyperplas-
tic lesions and a dramatic early angiogenic switch that in turn 
accelerates the transition to malignancy. These data strongly 
argue for the role of the angiogenic switch in regulating the 
malignant transition and for macrophages to be important 
players in this regulation (Lin and Pollard, 2007). These studies 
also show that macrophages play a significant role in vascu-
lar remodeling as tumors progress to late carcinoma stages 
(Lin et al., 2006). A similar macrophage depletion strategy also 
reduces angiogenesis in an osteosarcoma model (Kubota 
et al., 2009). Further, most TAM depletion strategies using 
liposome-encapsulated clodronate, described above, inhibit 
angiogenesis in transplanted tumor models (Gazzaniga et al., 
2007; Halin et al., 2009; Kimura et al., 2007; Zeisberger et al., 
2006). This effect seems to be the most likely cause of reduced 
tumor growth after macrophage depletion seen in these trans-
plants models, as their growth is very dependent upon rapid 
angiogenesis.
A subpopulation of CD11b-positive myeloid cells character-
ized by expression of Tie2, a marker of mature endothelial cells, 
has been described in tumors. These myeloid cells appear to 
be derived from Tie2-expressing monocytes that are found 
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in human cancer patients and in mice (Murdoch et al., 2008). 
Coinjection of tumor cells with these cells enhances angiogen-
esis. In contrast, ablation of these cells impairs angiogenesis in 
several mouse models of cancer (De Palma et al., 2005). Tran-
scriptional profiling of Tie2-positive and -negative monocytes 
shows that they are distinct classes, although highly related 
(Pucci et al., 2009). We have also identified two subpopula-
tions of macrophages in the PyMT model that express differing 
levels of Tie2 (data not shown). They are probably equivalent 
to the two populations described by Pucci et al. (2009), who 
defined their populations by a reporter gene assay rather than 
the more sensitive analysis of cell surface markers by fluores-
cence-activated cell sorting. Indeed, Tie2 messengar RNA 
(mRNA) is expressed in the Tie2-negative population albeit at 
a 20-fold lower level than the expression in the Tie2-positive 
population (Pucci et al., 2009).
Transcriptional profiling on high-density oligonucleotide 
arrays of these TAMs shows that they are highly enriched in 
transcripts that encode angiogenic molecules (Ojalvo et al., 
2009). Reinforcing this result, in the PyMT mammary cancer 
model, gene ablation of the Ets2 transcription factor in the 
myeloid lineage inhibits angiogenesis. Transcriptional profil-
ing of the Ets2-deficient TAMs shows that ETS2 controls the 
expression of transcripts encoding proteins that regulate 
angiogenesis (Zabuawala et al., 2010). In both cases, compari-
sons of TAM transcriptomes with available clinical databases 
shows that these transcriptional signatures are predictive of 
survival (Ojalvo et al., 2009; Zabuawala et al., 2010). These data 
make a strong case that this population of TAMs plays impor-
tant roles in tumor progression through their effects on angio-
genesis. Moreover, the proangiogenic role of TAMs in mouse 
models is consistent with clinical observations in breast cancer 
that correlate macrophage density with increased microvessel 
density and poor prognosis (Leek and Harris, 2002).
Hypoxia is a major driver of angiogenesis. Macrophages 
accumulate in hypoxic areas of the tumor and are particularly 
associated with necrotic tissue (Murdoch et al., 2008). HIF1α, 
whose expression is constitutive in macrophages, modulates 
the recruitment of macrophages to hypoxic regions of the 
tumor. This recruitment is through chemokines, especially 
CCL-2 and endothelins (Grimshaw et al., 2002; Murdoch et al., 
2008). At the hypoxic site, HIF1α regulates the transcription of 
a large panel of genes associated with angiogenesis, including 
VEGF (Lewis and Hughes, 2007; Murdoch et al., 2008). These 
genes then mediate the revascularization of the necrotic zones 
(Murdoch et al., 2008). This process can be modeled in in vivo 
angiogenesis models such as in T47D tumor cell spheroids 
(Murdoch et al., 2008) or in transplant tumor models (Zumsteg 
and Christofori, 2009).
Macrophages produce VEGF in both human and mouse 
mammary tumors (Leek and Harris, 2002; Lin et al., 2006). 
VEGF overexpression in macrophage-depleted mice increases 
vascularization and also accelerates the transition to malig-
nancy (Lin et al., 2007). This rescue is also associated with the 
recruitment of macrophages even in the absence of CSF-1, 
and these cells and their angiogenesis-regulating gene prod-
ucts may be partially responsible for the angiogenic response. 
Targeted ablation of the Vegfa gene in myeloid cells results 
in the inhibition of the angiogenic switch (Stockmann et al., 
2008). However, despite the failure of the angiogenic switch, 
the tumors that grow out are more aggressive and are char-
acterized by a less dense but more coherent vasculature. This 
aggressive growth suggests strong selection in response to 
hypoxic stress for tumor cells that are able to use glycolysis as 
a source for energy (Stockmann et al., 2008).
Macrophages can produce VEGF, but in other cases they 
also make it bioavailable through the production of MMP9, 
which releases VEGF from extracellular depots. Targeting of 
macrophages with bisphosphonate in a model of cervical car-
cinogenesis inhibits angiogenesis because macrophages are 
the major producers of MMP9 in this model and are recruited 
by CCL2 (Giraudo et al., 2004). Lack of CCL2 signaling reduces 
macrophage infiltration but has only a modest effect on tumor 
progression because of a compensatory recruitment of 
MMP9-producing neutrophils (Pahler et al., 2008). However, in 
other reports CCL2 recruitment of macrophages is required for 
angiogenesis (Fujimoto et al., 2009; Gazzaniga et al., 2007). 
In a glioblastoma mouse model, stromal-synthesized SDF-1 
(CXCL12) recruits a myeloid cell population that expresses 
MMP9 and releases matrix-bound VEGF. This VEGF stimulates 
not only angiogenesis but also tumor cell invasion (Du et al., 
2008).
Immunoregulation
Macrophages are central to many immune responses and 
are clearly immunoregulatory cells within the tumor. In some 
cases, this can result in rejection, as both macrophages and 
dendritic cells are able to present antigens to cytotoxic T 
cells and macrophages are adept at tumor killing. Pioneer-
ing work from Fidler and colleagues indicated that activated 
macrophages can kill tumor cells and eliminate metastases 
(Fidler and Schroit, 1988). Similarly, inhibition of tumor growth 
in xenograft models have recently been obtained by activat-
ing macrophages by either overexpressing GM-CSF (Eubank 
et al., 2009) or treating tumors with CpG together with anti-
IL10 (Guiducci et al., 2005). These latter treatments activate 
Toll-like receptors and block immunosupression, respec-
tively. However, in the vast majority of tumors, there does not 
appear to be substantial immunological limitation of tumor 
growth. This suggests that the tumor microenvironment sup-
presses any immune response and alters the phenotype to 
one that promotes the tumor (Swann et al., 2008). The exact 
role of macrophages or their cousins in this process has not 
been fully delineated. Phenotyping of the transcriptome of 
TAMs has suggested that they represent an immunological 
regulatory type. This is characterized by downregulation of 
transcripts involved with immunological activation such as 
IL-12, IL-18, and the TLR signaling pathway and upregulation of 
transcripts found in alternatively activated macrophages such 
as arginase (Biswas et al., 2006; Ojalvo et al., 2009). Impor-
tantly in the PyMT model this polarization of macrophages is 
caused by IL-4 synthesized by CD4-positive T cells (DeNardo 
et al., 2009). Furthermore, macrophages in tumors develop in 
high concentrations of CSF-1 that support their differentia-
tion to trophic macrophages and away from immunologically 
activated ones, which are controlled by GM-CSF (Hamilton, 
2008; Mantovani and Sica, 2010).
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Macrophages can inhibit cytotoxic T cell responses through 
several mechanisms. For example, macrophages produce IL-10 
that in turn induces monocytes to express the costimulatory 
molecule programmed death ligand (PD)-L1 and suppresses 
cytotoxic T cell responses (Kuang et al., 2009). Macrophages 
in human ovarian cancers produce CCL22, a chemokine that 
regulates the influx of regulatory T cells (Tregs) that suppress 
cytotoxic T cell responses. The abundance of these Tregs in 
ovarian cancer predicts poor survival (Curiel et al., 2004). In 
mammary tumor xenografts, a newly recruited macrophage 
population suppressed immune responses through synthesis 
of PGE2 and TGF-β (Torroella-Kouri et al., 2009).
Myeloid-derived suppressor cells (MDSCs) are another 
immunosuppressive immune cell population related to mac-
rophages that has come to the forefront in recent years. 
MDSCs are a mixed population of myeloid cells that accumu-
late in pathological conditions including cancer. Morphologi-
cally, these populations consist of monocytes, granulocytes, 
and immature myeloid cells and are identified by their capac-
ity to suppress cytotoxic T cell responses (Gabrilovich and 
Nagaraj, 2009). In mice, MDSCs express both the myeloid cell 
marker CD11b and the granulocyte marker Gr1. The presence 
of these markers satisfies the classical definition of neutro-
phils, and therefore MDSCs are not mononuclear phagocytes 
(Gabrilovich and Nagaraj, 2009). This cell surface marker anal-
ysis has also been reinforced by gene expression analysis that 
shows that MDSCs are markedly different from TAMs (Pucci et 
al., 2009). However, a key question remains whether these cells 
can differentiate solely into mature granulocytes or whether 
they can become macrophages in vivo and whether there are 
other more myeloid subpopulations of these cells.
Macrophages at the Metastatic Site
Most studies have focused upon events occurring in the primary 
tumor, often with metastasis as an end point. However, metas-
tasis requires not only the release of cells from the primary 
site but also their transit through the circulation or lymphatics 
to arrive at a distant site where the cells need to extravasate, 
survive, and prosper. This process of metastasis is very inef-
ficient. In humans, there are many thousands of circulating 
cells released by tumors every day, but only a few successfully 
make metastases. In fact, the most likely fate for these cells is 
death, with extravasation and establishment of micrometasta-
ses being major rate-limiting events (Joyce and Pollard, 2009). 
Although it has long been known that macrophages populate 
metastatic lesions (Joyce and Pollard, 2009), only recently has 
their role in metastasis been appreciated.
Cancer is a systemic disease, and primary tumors secrete 
factors that influence metastatic outcome at distant sites. 
For example, the tumor-derived extracellular matrix protein, 
versican, stimulates metastasis in the Lewis lung carcinoma 
model through TLR2 signaling in myeloid cells (Kim et al., 
2009). Aggressive tumors systemically influence less aggres-
sive indolent ones to grow faster and to stimulate the growth 
of micrometastases through the acquisition of bone marrow-
derived cells. In these studies, osteopontin expressed from 
the aggressive tumor has been shown to be necessary but not 
sufficient for the mobilization of bone marrow cells (McAllister 
et al., 2008). In neither study was the phenotype of the bone 
marrow cells that influence the metastatic site fully character-
ized; however, it is likely that macrophages are major players 
in these responses.
Primary tumors have also been shown to cause the accumu-
lation myeloid derived cells at distant sites, and this process 
enhances metastatic efficiency (Kaplan et al., 2005). These 
primed sites are termed the premetastatic niche. Their location 
can be altered, for example from lung to bone, by serum condi-
tioned by the primary tumor giving organ specificity to the metas-
tases (Kaplan et al., 2005). Among the tumor-produced factors 
required for the premetastatic niche are the myeloid chemoat-
tractants S100A8 and A9, whose synthesis is induced by the pri-
mary tumor. S100 proteins induce the synthesis of amyloid pro-
tein A that signals through TLR4 in myeloid and endothelial cells 
(Hiratsuka et al., 2006; Hiratsuka et al., 2008). In addition, lysyl 
oxidase crosslinks the collagen at the premetastatic site and is 
essential for the myeloid recruitment (Erler et al., 2009). These 
myeloid cells secrete MMP9 that releases matrix-bound VEGF, 
whose function is in turn required for the increase in metastatic 
efficiency (Hiratsuka et al., 2002). Although the myeloid cells 
that accumulate in these niches have not been fully character-
ized, they are CD11b- and VEGFR1-positive, characteristics of 
mononuclear phagocytic cells (Hiratsuka et al., 2006; Kaplan et 
al., 2005). Inhibition of VEGFR1 signaling by antibody inhibition 
or receptor mutation also inhibits the formation of the premeta-
static niche (Hiratsuka et al., 2002; Kaplan et al., 2005). However, 
there is a contradictory report challenging these findings, albeit 
in a different model of metastasis (Dawson et al., 2009). It has 
been proposed that these niches provide sites for tumor cells 
to adhere and prosper (Psaila and Lyden, 2009). Alternatively, 
these niches might simply prepare the tissue for successful 
colonization by being a reservoir of monocytes that can be rap-
idly mobilized to differentiate into macrophages in response to 
incoming tumor cells, a process that enhances metastatic seed-
ing and growth (Qian et al., 2009).
Metastatic cells can colonize and grow in particular tissues 
even in the absence of a primary tumor (Joyce and Pollard, 
2009). Recent ex vivo imaging studies of lungs indicate that 
macrophages are recruited to these extravasating tumor cells 
and ablation of these macrophages dramatically reduce the 
extravasation efficiency and the subsequent tumor cell survival 
such that metastatic cell seeding efficiency is markedly reduced 
(Qian et al., 2009). Furthermore, ablation of these recruited 
macrophages limits subsequent metastatic growth, even after 
metastatic lesions had been established. These effects were 
accompanied by physical interactions between macrophages 
and metastatic tumor cells, suggesting short-range transmis-
sion of growth and survival signals (Qian et al., 2009). Phenotyp-
ing revealed that the metastasis-associated macrophages differ 
from the CD11c-positive lung interstitial resident macrophages. 
Instead, they are regulated by CSF-1 and characterized by cell 
surface expression of CD11b, F4/80, VEGFR1, and CCR2 and 
the absence of Gr1 and low CD11c (Qian et al., 2009). Thus, this 
prometastatic macrophage is another population with a distinct 
phenotype (Figure 2) that is found not only in these experimen-
tal models but also in metastases derived from autochthonous 
(spontaneous and native) models (Qian et al., 2009).
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In summary, mononuclear phagocytes appear not only to 
set up preferred sites for metastatic cell seeding but also to 
enhance tumor cell extravasation, establishment, and subse-
quent growth of metastatic lesions (Figure 3).
Perspectives
Malignant cells can be reverted to a quiescent differentiated 
state by incorporation into an embryonic microenvironment 
(Joyce and Pollard, 2009). This indicates the microenvironment 
is dominant over malignancy. Thus, for tumors to progress and 
become malignant they must manipulate their microenviron-
ment to one that is at least permissive if not promoting. This is 
probably due to selection of oncogenic mutations that lead to 
secretion of molecules that alter the cellular composition and 
function of the microenvironment. Among these changes is 
the recruitment of bone marrow-derived cells, of which mac-
rophages are particularly abundant. Macrophages in primary 
and secondary tumors confer several properties that enhance 
progression and metastasis. Each function is affected by a 
particular macrophage subpopulation (Figure 2). Elsewhere, we 
have reviewed data that macrophages play important trophic 
roles during development and have argued that these roles are 
recapitulated in tumors (Pollard, 2009). This conjecture is sup-
ported by transcriptome analysis on high-density arrays that 
show the TAMs are most similar to macrophages involved in 
developmental processes (Ojalvo et al., 2009). These trophic 
macrophages are also characterized as immunomodulatory 
as would be expected for cells involved in normal processes. 
However, in contrast to developing systems, tumors have lost 
their “off” switches because of oncogenic mutations, thus 
losing control of positional identity. Consequently, tumors 
continue to inappropriately call for trophic support from mac-
rophages. This leads to macrophage enhancement of malig-
nancy at every step of the way.
Undoubtedly, as we dig deeper many other macrophage 
subpopulations will be revealed. For example, macrophages in 
prostate cancer cause the tumor cells to become resistant to 
the inhibitory effects of therapeutic androgen receptor antago-
nists, and instead these drugs become agonists for growth. 
This resistance is mediated by transcriptional cofactor TAB2, 
which acts as a sensor of inflammation in the form of IL-1β and 
whose phosphorylation causes release of gene transcription 
that is normally repressed by the antiandrogen. Similar mecha-
nisms operate with antiestrogens in MCF-7 breast cancer cells 
(Zhu et al., 2006). Macrophages might therefore have a further 
protumor function in the progression of sex steroid hormone-
dependent cancers to steroid independence.
Many experimental challenges remain. For example, cau-
tion needs to be exercised in the interpretation of experiments 
involving tumor transplantation, often into immunocompe-
tent animals. These experiments are confounded by antigraft 
reactions even in syngeneic contexts, as well as the skewed 
immune reactions in immunocompromised mice. They cannot 
represent the subtlety of immune cell interactions that occurs 
during the progression of autochthonous tumors. Thus, for 
macrophage biology, immune-competent animals need to 
be used, and although valuable results can be obtained from 
transplant experiments, the conclusions need to be validated in 
models of spontaneously arising tumors. Another challenge is 
to confirm that the macrophage subtypes and functions found 
in rodents are present in human tumors. It is likely that com-
parable macrophage populations exist given that the individual 
TAM expression signatures derived from mice are represented 
in human tumor datasets and can even be predictive (Ojalvo 
et al., 2009; Zabuawala et al., 2010). Yet, this validation of the 
rodent data in humans is essential before antimacrophage 
therapeutics are designed.
The evidence that macrophages provide tropic support 
to tumors and the genetic experiments that show that if you 
remove this support malignancy is suppressed strongly argue 
that these cells or their unique signaling pathways are therapeu-
tic targets. Unlike tumor cells, the genomes of macrophages 
are stable, suggesting that they may not as readily become 
drug resistant. Significant progress has been made in identify-
ing the molecular basis for both macrophage phenotypes and 
their actions in promoting specific aspects of tumor behavior. 
Some important signaling pathways have been defined as 
described above, including those in response to VEGFa, TNFα, 
EGF, and CSF-1. In addition, some transcriptional regulators 
(NFκB, STAT3) that bias macrophage phenotypes from pro- to 
Figure 3. Macrophages Promote Seeding and Growth of Metastatic 
Cells
Myeloid cells, most likely macrophages, are recruited to the premetastatic 
niche in response to secreted products from the primary tumor. The metastat-
ic target organs contain fibroblasts and elaborate extracellular matrix consist-
ing of fibronectin and collagen. These niches direct and enhance tumor cell 
seeding in sites distant from the primary tumor. Once the tumor cells arrive at 
the metastatic site and begin to extravasate, they recruit macrophages that 
are differentiated from blood borne monocytes. These macrophages enhance 
the ability of tumors cells to extravasate and promote their subsequent surviv-
al and growth. They continue to accumulate in metastatic lesions, where they 
stimulate the growth and survival of the metastatic cells. Several growth fac-
tors and signaling pathways are important for these macrophage functions, 
including vascular endothelial growth factor (VEGFR) in the premetastatic site 
and colony stimulating factor-1 (CSF-1).
48 Cell 141, April 2, 2010 ©2010 Elsevier Inc.
antitumoral and molecules that recruit these cells to tumors 
such as CCL-2 have been identified. Panmacrophage inhibitors 
such as drugs that inhibit CSF-1 signaling are in early clinical 
trials. However, in the future there may also be targeted thera-
pies that uniquely strike macrophages in the tumor microen-
vironment and macrophage therapeutics that enhance the 
activities of conventional treatments.
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Note Added in Proof
During the production of this review, data reinforcing the role of macrophages 
in the progression of Hodgkin’s lymphoma (Steidl, C., Lee, T., Shah, S.P., 
Farinha, P., Han, G., Nayar, T., Delaney, A., Jones, S.J., Iqbal, J., Weisen-
burger, D.D. et al. [2010]. N. Engl. J. Med. 362, 875–885), in angiogenesis 
(Priceman, S.J., Sung, J.L., Shaposhnik, Z., Burton, J.B., Torres-Collado, A.X., 
Moughon, D.L., Johnson, M., Lusis, A.J., Cohen, D.A., Iruela-Arispe, M.L., 
and Wu, L. [2010]. Blood 115, 1461–1471), and in tumor growth (Loges, S., 
Schmidt, T., Tjwa, M., van Geyte, K., Lievens, D., Lutgens, E., Vanhoutte, D., 
Borgel, D., Plaisance, S., Hoylaerts, M. et al. [2010]. Blood 115, 2264–2273) 
were published.
